| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f95a7cde1d730a51ce9be7d769177713 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2223-108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2223-419
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2223-612
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2223-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N23-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-485 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N23-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 |
| filingDate |
2020-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41b2ab3c405e5590ac67d5c9b56008d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e1dc7219bfe380c8209edfaca00e2b8 |
| publicationDate |
2022-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022160902-A1 |
| titleOfInvention |
[18F]-Labeled Benzothiazole Derivative As PET Radiotracer |
| abstract |
The present disclosure relates to [ 18 F]-labeled benzothiazole derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in in vivo diagnosis, preclinical and clinical imaging, patient stratification on the basis of mutational status of c-abl and assessing response to therapeutic treatments. The present disclosure further relates to the use of [ 18 F]-labeled benzothiazole derivatives as PET radiotracers. The disclosure also provides a process for the radiosynthesis of [ 18 F]-labeled benzothiazole derivatives. |
| priorityDate |
2019-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |